The forecasted sold production of hormones, prostaglandins, thromboxanes, and leukotrienes in Italy indicates a steady upward trend from 2024 to 2028. Starting from a value of 533.49 million euros in 2024, it is anticipated to rise to 578.71 million euros by 2028. In 2023, the industry stood at a similar level to 2024, around 533.49 million euros. This data reflects consistent growth year-on-year, with an average increase of roughly 2.0% based on compound annual growth rate (CAGR) for the period.

Future trends to watch for include:

Advancements in biotechnology and synthetic production methods potentially impacting production costs and output.
Regulatory changes in Italy and the EU that might affect market dynamics.
Increasing demand for hormone-related products in the medical and pharmaceutical industries.
Market competition and innovation among key players in the sector, possibly influencing market share and pricing strategies.